Xiao Qing Lewell

This inventor holds 12 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Glaxo Group Limited, Glaxosmithkline LLC. Active years: 2006-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiao Qing Lewell. Retrieved from https://idiyas.com/inventor/xiao-qing-lewell

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 2)

% Patents Active = 58.3

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 6.8

ph-index = 4

Forward Citations = 51(Granted Patents)

Company Filing History:

Years Active: 2006-2018

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10117873 - 6-amino-purin-8-one compounds (2018-11-06),

2. 9877968 - 6-amino-purin-8-one compounds (2018-01-30),

3. 9346806 - 6-amino-purin-8-one compounds (2016-05-24),

4. 9233962 - Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases (2016-01-12),

5. 8765772 - Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases (2014-07-01),

6. 8067426 - 6-amino-purin-8-one compounds (2011-11-29),

7. 7622464 - Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases (2009-11-24),

8. 7560548 - Morpholin-acetamide derivatives for the treatment of inflammatory diseases (2009-07-14),

9. 7288564 - Indole derivatives (2007-10-30),

10. 7232821 - (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives (2007-06-19),

11. 7157457 - Compounds useful in the treatment of inflammatory diseases (2007-01-02),

12. 7101882 - Morpholin-acetamide derivatives for the treatment of inflammatory diseases (2006-09-05),

Title: The Innovative Contributions of Xiao Qing Lewell

Introduction

Xiao Qing Lewell, a prolific inventor based in Stevenage, GB, has made significant strides in the field of pharmaceuticals, particularly in the development of compounds that induce human interferon. With a total of 12 patents to his name, Lewell's work showcases the intersection of chemistry and medicine, aiming to address various health disorders.

Latest Patents

Among his latest innovations are the 6-amino-purin-8-one compounds. These compounds are described by a specific formula where R can be Calkylamino, Calkoxy, or Ccycloalkyloxy. Both m and n are integers defining the structure of the molecule, contributing to its functionality as an inducer of human interferon. The implications of these compounds are vast, as they may offer therapeutic benefits in treating allergic diseases, inflammatory conditions such as allergic rhinitis and asthma, infectious diseases, and even cancer. Additionally, they hold the potential to enhance vaccine efficacy.

Career Highlights

Lewell has worked with well-known organizations like GlaxoSmithKline LLC and Glaxo Group Limited. His experience in these companies has allowed him to hone his skills and contribute to significant advancements in pharmaceutical research and development.

Collaborations

Throughout his career, Lewell has collaborated with esteemed colleagues, including Keith Biggadike and Diane Mary Coe. These partnerships have enriched his work and facilitated the successful development of his inventive compounds.

Conclusion

In conclusion, Xiao Qing Lewell's dedication to innovation in the pharmaceutical sector reflects his commitment to improving healthcare outcomes. His contributions, particularly in the realm of human interferon-inducing compounds, may lead to groundbreaking therapies for a variety of medical challenges. With a strong foundation of patents and collaboration, Lewell continues to be a notable figure in the landscape of biomedical innovation.

Profile summary based on public USPTO records.